Practical Aspects of the Use of Carfilzomib in Multiple Myeloma

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma

Carfilzomib (Kyprolis®, Amgen), a second-generation proteasome inhibitor, is capable of covalent bonding and irreversible inhibition of the 20S proteasome chymotrypsin-like activity. In 2016 this drug was approved in Russia for monotherapy of relapsed refractory multiple myeloma (MM) and in combinat...

Full description

Bibliographic Details
Main Authors: SV Semochkin, GN Salogub, SS Bessmeltsev, KD Kaplanov
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2018-12-01
Series:Kliničeskaâ onkogematologiâ
Subjects:
proteasome inhibitor
lenalidomide
bortezomib
multiple myeloma
renal failure
carfilzomib
cytogenetic risk
Online Access:http://bloodjournal.ru/wp-content/uploads/2018/12/3-1.pdf

Internet

http://bloodjournal.ru/wp-content/uploads/2018/12/3-1.pdf

Similar Items